Haematologica EWOG-MDS website
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barbui, T
Right arrow Articles by Tura, S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barbui, T
Right arrow Articles by Tura, S
Haematologica, Vol 89, Issue 2, 215-232
Copyright © 2004 by Ferrata Storti Foundation

Consensus Development Conference

Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation

T Barbui, G Barosi, A Grossi, L Gugliotta, LN Liberato, M Marchetti, MG Mazzucconi, F Rodeghiero, and S Tura

Divisione di Ematologia. Spedali Riuniti, Bergamo, Italy.

BACKGROUND AND OBJECTIVES: The Italian Society of Hematology (SIE) and the two affiliated Societies (SIES and GITMO) commissioned a project to develop guidelines for the therapy of essential thrombocythemia (ET) using evidence-based knowledge and consensus formation techniques. DESIGN AND METHODS: Key questions on the optimal management of ET patients were formulated by an Advisory Council (AC) and approved by an Expert Panel (EP) composed of 7 senior hematologists. The AC systematically reviewed the published literature from 1980 to August 2002, and articles were graded according to their internal validity and quality. Using the Delphi technique, the EP was asked to answer the key questions according to the available evidence. From September 2002 to March 2003, four Consensus Conferences were held in accordance with the Nominal Group Technique with the goal of solving residual disagreement on recommendations. RESULTS: The EP provided recommendations on when to start platelet-lowering therapy, the most appropriate platelet-lowering agent, the use of anti-platelet therapy, and the management of women in childbearing age and of pregnant women. INTERPRETATION AND CONCLUSIONS: By using evidence and consensus, recommendations for the treatment of key problems in ET have been issued. Statements are graded according to the strength of the supporting evidence and uncertainty is explicitly declared.


This article has been cited by other articles:


Home page
 JCOHome page
A. Carobbio, E. Antonioli, P. Guglielmelli, A. M. Vannucchi, F. Delaini, V. Guerini, G. Finazzi, A. Rambaldi, and T. Barbui
Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia
J. Clin. Oncol., June 1, 2008; 26(16): 2732 - 2736.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
V. De Stefano, T. Za, E. Rossi, A. M. Vannucchi, M. Ruggeri, E. Elli, C. Mico, A. Tieghi, R. R. Cacciola, C. Santoro, et al.
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments
Haematologica, March 1, 2008; 93(3): 372 - 380.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Ruggeri, F. Rodeghiero, A. Tosetto, G. Castaman, F. Scognamiglio, G. Finazzi, F. Delaini, C. Mico, A. M. Vannucchi, E. Antonioli, et al.
Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey
Blood, January 15, 2008; 111(2): 666 - 671.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. M. Vannucchi, E. Antonioli, P. Guglielmelli, A. Rambaldi, G. Barosi, R. Marchioli, R. M. Marfisi, G. Finazzi, V. Guerini, F. Fabris, et al.
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia
Blood, August 1, 2007; 110(3): 840 - 846.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
A. M. Vannucchi and T. Barbui
Thrombocytosis and Thrombosis
Hematology, January 1, 2007; 2007(1): 363 - 370.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Tefferi, N. Gangat, and A. P. Wolanskyj
Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter?
Blood, October 1, 2006; 108(7): 2493 - 2494.
[Full Text] [PDF]

Home page
 BloodHome page
A. I. Schafer
Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia
Blood, June 1, 2006; 107(11): 4214 - 4222.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
T. Barbui and G. Finazzi
Myeloproliferative Disease in Pregnancy and Other Management Issues
Hematology, January 1, 2006; 2006(1): 246 - 252.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
C.-S. Chim, Y.-L. Kwong, A. K.-W. Lie, S.-K. Ma, C.-C. Chan, L.-G. Wong, B. C. San Kho, H.-K. Lee, J. P.-Y. Sim, C.-H. Chan, et al.
Long-term Outcome of 231 Patients With Essential Thrombocythemia: Prognostic Factors for Thrombosis, Bleeding, Myelofibrosis, and Leukemia
Arch Intern Med, December 12, 2005; 165(22): 2651 - 2658.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
T. Barbui and G. Finazzi
When and How to Treat Essential Thrombocythemia
N. Engl. J. Med., July 7, 2005; 353(1): 85 - 86.
[Full Text] [PDF]

Home page
 ASH Education BookHome page
C. N. Harrison
Platelets and Thrombosis in Myeloproliferative Diseases
Hematology, January 1, 2005; 2005(1): 409 - 415.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2004 by the Ferrata Storti Foundation.